Drugs / CT-868
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05794581 | Mar 2023 → Mar 2024 | type 1 diabetes mellitus | Carmot Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04973111 | Jul 2021 → Apr 2022 | diabetes mellitus | Carmot Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06062069 | Oct 2023 → Jul 2025 | obesity disorder, type 1 diabetes mellitus | Carmot Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05110846 | Feb 2022 → Feb 2023 | obesity disorder, type 2 diabetes mellitus | Carmot Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-868 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06062069 ↗ |
| Route | Subcutaneous | “SC dose of CT-868” NCT04973111 ↗ |